STRO vs. TARS, FDMT, BCRX, AUTL, IMTX, MESO, RLAY, HUMA, SRRK, and PRME
Should you be buying Sutro Biopharma stock or one of its competitors? The main competitors of Sutro Biopharma include Tarsus Pharmaceuticals (TARS), 4D Molecular Therapeutics (FDMT), BioCryst Pharmaceuticals (BCRX), Autolus Therapeutics (AUTL), Immatics (IMTX), Mesoblast (MESO), Relay Therapeutics (RLAY), Humacyte (HUMA), Scholar Rock (SRRK), and Prime Medicine (PRME). These companies are all part of the "biological products, except diagnostic" industry.
Sutro Biopharma (NASDAQ:STRO) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.
97.0% of Sutro Biopharma shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 5.9% of Sutro Biopharma shares are held by insiders. Comparatively, 8.3% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Sutro Biopharma has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Tarsus Pharmaceuticals had 4 more articles in the media than Sutro Biopharma. MarketBeat recorded 5 mentions for Tarsus Pharmaceuticals and 1 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.87 beat Tarsus Pharmaceuticals' score of 1.03 indicating that Sutro Biopharma is being referred to more favorably in the media.
Sutro Biopharma has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.
Sutro Biopharma presently has a consensus price target of $12.50, suggesting a potential upside of 195.86%. Tarsus Pharmaceuticals has a consensus price target of $50.38, suggesting a potential upside of 52.84%. Given Sutro Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Sutro Biopharma is more favorable than Tarsus Pharmaceuticals.
Sutro Biopharma received 81 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. Likewise, 64.74% of users gave Sutro Biopharma an outperform vote while only 64.62% of users gave Tarsus Pharmaceuticals an outperform vote.
Tarsus Pharmaceuticals has a net margin of 0.00% compared to Sutro Biopharma's net margin of -74.61%. Tarsus Pharmaceuticals' return on equity of -71.12% beat Sutro Biopharma's return on equity.
Summary
Sutro Biopharma beats Tarsus Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Sutro Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sutro Biopharma Competitors List
Related Companies and Tools
